Inclusion Criteria:

• Histologically or cytologically confirmed Stage IIIb or IV NSCLC
• Has metastatic disease at time of study entry
• Has a tumor measurable according to RECIST guidelines
• Age ≥ 18 years
• Has an ECOG performance status of 0 -1 (Karnofsky ≥ 80)
• If patient has received prior adjuvant chemotherapy, the last dose of adjuvant treatment was administered at least 6 months prior to randomization
• Has adequate hematologic function as defined by absolute neutrophil count (ANC) and platelet count within normal limits
• Has adequate hepatic function as defined by a total bilirubin ≤ 1.5 x the ULN, and AST and ALT ≤ 3 x the ULN (or ≤ 5 x the ULN in the presence of known liver metastases)
• Has adequate renal function as defined by serum creatinine ≤ 1.5 x the institutional ULN. If creatinine is above the ULN, the patient's creatinine clearance is ≥ 60 mL/min.
• Has fasting serum glucose < 120mg/dL or below the ULN
• Because the teratogenicity of IMC-A12 is not known, women of childbearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation
• Has the ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

• Has uncontrolled brain metastases
• Has leptomeningeal disease
• Has received previous chemotherapy for NSCLC (patients who have received adjuvant chemotherapy are eligible if the last administration of the prior adjuvant regimen occurred at least 6 months prior to randomization
• Is receiving any other investigational agents
• Has a history of treatment with other agents targeting the IGF or the EGF receptor
• Has a history of allergic reactions attributed to compounds of chemical or biologic composition similar to that of IMC-A12 or Cetuximab
• Has poorly controlled diabetes mellitus. Patients with a history of diabetes mellitus are allowed to participate, provided that their blood glucose is within normal range (fasting glucose < 120mg/dL or below the ULN) and that they are on a stable dietary or therapeutic regimen for this condition.
• Has an uncontrolled intercurrent illness, including, but not limited to, ongoing or active infection requiring parenteral antibiotics, symptomatic congestive heart failure, uncontrolled hypertension, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Is pregnant or lactating
• Has a history of another primary cancer, with the exception of: a) curatively resected nonmelanomatous skin cancer; b) curatively treated cervical carcinoma in situ; or c) other primary solid tumor treated with curative intent and no known active disease present and no treatment administered during the last 3 years